<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Frumovitz, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cancer of the uterine cervix is the third most common gynecologic cancer diagnosis and cause of death among gynecologic cancers in the United States [<a href="#rid1">1</a>]. Cervical cancer has lower incidence and mortality rates than uterine corpus and ovarian cancer, as well as many other cancer sites. However, in countries that do not have access to cervical cancer screening and prevention programs, cervical cancer remains a significant cause of cancer morbidity and mortality.</p><p>Human papillomavirus (HPV) is central to the development of cervical neoplasia and can be detected in 99.7 percent of cervical cancers [<a href="#rid2">2</a>]. The most common histologic types of cervical cancer are squamous cell (70 percent of cervical cancers) and adenocarcinoma (25 percent) [<a href="#rid3">3</a>]. </p><p>The epidemiology, risk factors, clinical manifestations, and diagnosis of invasive cervical cancer will be reviewed here. Screening and prevention, staging, and the management of cervical cancer and preinvasive disease are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management"</a>.)</p><p></p><p>In this topic, we will use the terms "female" or "patient" to describe genetic females. We recognize that not all people with cervical cancer identify as female, and we encourage the reader to consider the specific counseling needs of transgender and gender nonbinary individuals.</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H7674594"><span class="h2">Incidence and mortality</span><span class="headingEndMark"> — </span>In 2020, cervical cancer accounted for an estimated 604,000 new cancer cases and 342,000 deaths worldwide [<a href="#rid4">4</a>] and was the fourth most common cancer in females [<a href="#rid5">5</a>]. Eighty-four percent of cervical cancer cases were from resource-limited regions [<a href="#rid6">6</a>]. In females in resource-limited countries, cervical cancer was the second most common type of cancer (15.7 per 100,000 females) and the third most common cause of cancer mortality (8.3 per 100,000). On the continent of Africa and in Central America, cervical cancer is the leading cause of cancer-related mortality among females [<a href="#rid4">4,7</a>]; at least one study suggests that the incidence of cervical cancer has been increasing in some parts of Africa since the early 2000s [<a href="#rid8">8</a>].</p><p>In the United States, approximately 13,960 new cases of invasive cervical cancer and 4310 cancer-related deaths occur each year [<a href="#rid1">1</a>]. Cervical cancer is the third most common cancer diagnosis and cause of death among gynecologic cancers in the United States, with lower incidence and mortality rates than uterine corpus or ovarian cancer.</p><p>Global incidence and mortality rates depend upon the presence of screening programs for cervical precancer and cancer and of human papillomavirus (HPV) vaccination, which are most likely to be available in resource-rich countries. (See  <a class="medical medical_review" href="/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a> and  <a class="medical medical_review" href="/d/html/3202.html" rel="external">"Screening for cervical cancer in resource-limited settings"</a> and  <a class="medical medical_review" href="/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>Due to these interventions, there has been a large downward trend (approximately 75 percent decrease) in the incidence and mortality of cervical cancer over the past 50 years in resource-rich countries [<a href="#rid9">9,10</a>], though there are some exceptions [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By some estimates, if vaccine rates of 70 percent worldwide are achieved, we would expect to see a decrease of 344,520 new cases of cervical cancer annually and avoid 178,182 cervical cancer-related deaths [<a href="#rid12">12</a>]. However, due to the latency period of 10 to 15 years between HPV exposure and cervical cancer development, there are not likely to be significant decreases in cervical dysplasia or cancer for many years after the implementation of vaccination programs. Surprisingly, in countries such as Australia that have achieved vaccination rates &gt;70 percent, there has already been a 38 percent reduction in high-grade dysplasia [<a href="#rid13">13</a>]. Even in countries with lower vaccination rates, such as the United States, there has been a decrease in the incidence of high-grade cervical dysplasia. As an example, in Connecticut between 2008 and 2011, the vaccination rate increased from 45 to 61 percent [<a href="#rid14">14</a>]. During that same time period, there was a decrease in high-grade cervical dysplasia of 18 percent. As high-grade dysplasia is a necessary precursor for squamous, adenocarcinoma, and adenosquamous carcinomas of the cervix, this sharp decrease in high-grade cervical dysplasia should translate into decreased incidence of cervical cancer in the next decade.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data suggest that cervical cancer screening in conjunction with HPV vaccination can greatly reduce the incidence of cervical cancer in resource-limited settings. These data are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3202.html" rel="external">"Screening for cervical cancer in resource-limited settings", section on 'Importance of HPV vaccination'</a>.)</p><p></p><p class="headingAnchor" id="H4184833886"><span class="h2">Race distribution</span><span class="headingEndMark"> — </span>Estimates of incidence and mortality for cervical cancer vary depending on race/ethnicity. The United States National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program reported estimates of new cancer cases and deaths (per 100,000 population) as follows [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>American Indian/Alaska Native (10.1 and 2.9)</p><p class="bulletIndent1"><span class="glyph">●</span>Hispanic American (10 and 2.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Non-Hispanic Black American (9 and 3.3)</p><p class="bulletIndent1"><span class="glyph">●</span>Non-Hispanic White American (7.1 and 2)</p><p class="bulletIndent1"><span class="glyph">●</span>Asian American or Pacific Islander (6.3 and 1.6) </p><p></p><p>A higher magnitude of difference in cervical cancer mortality between Black and White females was found in a United States national survey [<a href="#rid16">16</a>]. The study excluded those who reported a prior hysterectomy (thereby changing the denominator and making the cervical cancer mortality rates higher overall) and found the following mortality rates: Black females (10.1 per 100,000) and White females (4.7 per 100,000). The study raises the question of whether there is a higher than previously calculated risk of cervical cancer mortality when only vulnerable females are included (those with a cervix). A limitation of the study is that no differentiation was made between total and supracervical hysterectomy.</p><p class="headingAnchor" id="H7674822"><span class="h2">Age distribution</span><span class="headingEndMark"> — </span>Worldwide in 2012, the cumulative risks of developing cervical cancer and of cervical cancer mortality by age 74 years were as follows: resource-rich countries (0.9 percent incidence/0.3 percent mortality) and resource-limited countries (1.6 percent/0.9 percent) [<a href="#rid6">6</a>]. </p><p>The lifetime risk of developing cervical cancer for United States females, based on national data from 2017 to 2019, was 0.7 percent [<a href="#rid15">15</a>]. The median age at diagnosis of cervical cancer in the United States from 2015 to 2019 was 50 years. Only 2.5 percent of cases were diagnosed in patients ages 85 years or older. In 2019, the United States hysterectomy- and age-adjusted incidence of cervical cancer in females &lt;24 years was 0.08 per 100,000, rising to 4 per 100,000 in females ages 25 to 29 years, and peaking at 19.2 per 100,000 in females ages 60 to 64 years [<a href="#rid17">17</a>]. Thus, some clinicians continue screening females with a prolonged life expectancy through age 74 [<a href="#rid16">16,18</a>]. (See  <a class="medical medical_review" href="/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings", section on 'Age &gt;65 years'</a>.)</p><p class="headingAnchor" id="H7674829"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The two major histologic types of cervical cancer, adenocarcinoma and squamous cell carcinoma, and the preinvasive disease that corresponds with these histologies share many of the same risk factors [<a href="#rid19">19-29</a>]. </p><p class="headingAnchor" id="H2561267890"><span class="h2">HPV-related</span><span class="headingEndMark"> — </span>In almost all cases, cervical cancer is due to human papillomavirus (HPV) infection. Risk factors that are associated with HPV-related cancers include: </p><p class="bulletIndent1"><span class="glyph">●</span>Early onset of sexual activity – Compared with age at first intercourse of 21 years or older, the risk is approximately 1.5-fold for 18 to 20 years and twofold for younger than 18 years [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple sexual partners – Compared with one partner, the risk is approximately twofold with two partners and threefold with six or more partners [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high-risk sexual partner (eg, a partner with multiple sexual partners, history of prior sexually transmitted disease[s], or known HPV infection).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of sexually transmitted infections (eg, Chlamydia trachomatis, genital herpes).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early age at first birth (younger than 20 years old) and increasing parity (three or more full-term births); these are likely due to exposure to HPV through sexual intercourse [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of vulvar or vaginal squamous intraepithelial neoplasia or cancer (HPV infection is also the etiology of most cases of these conditions).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppression (eg, HIV infection).</p><p></p><p class="headingAnchor" id="H2938474973"><span class="h2">Non-HPV-related</span></p><p class="bulletIndent1"><span class="glyph">●</span>Low socioeconomic status – In the United States, cervical cancer incidence and mortality are higher in patients who live in communities with higher poverty levels compared with lower poverty levels, likely due to limited access to health care and screening programs [<a href="#rid30">30-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contraceptive use</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral contraceptives – A collaborative analysis of data from 24 epidemiologic studies found that, among current users of oral contraceptives, the risk of invasive cervical cancer increased with increasing duration of use (≥5 years of use versus never use: relative risk [RR] 1.9, 95% CI 1.69-2.13). The risk declined after use ceased, and by 10 or more years had returned to that of never users [<a href="#rid28">28</a>]. A systematic review that included 12 studies of patients with cervical cancer found that, in those who were known to be HPV positive, increased duration of oral contraceptive use was associated with an increase in the rate of cervical cancer [<a href="#rid33">33</a>]. The incidence of cervical cancer by duration of use included the following: 5 to 9 years (odds ratio [OR] 2.82) and ≥10 years (OR 4.03). While some studies suggest that adenocarcinoma appears to have a stronger association with oral contraceptives than does squamous cell cancer [<a href="#rid34">34</a>], others found a similar risk increase with increasing duration of oral contraceptives for both adeno- and squamous cell carcinomas [<a href="#rid35">35</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intrauterine device – By contrast, both the copper and <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> intrauterine devices (IUDs) may be associated with <strong>lower</strong> rates of cervical cancer [<a href="#rid36">36</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Benefits'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoking – Smoking is associated with an increased risk of <strong>squamous</strong> cell carcinoma of the cervix but not of adenocarcinoma [<a href="#rid19">19,25</a>]. In one study, smoking increased the risk of squamous carcinoma by approximately 50 percent (RR 1.50, 95% CI 1.35-1.66) but did not increase the risk of adenocarcinoma (RR 0.86, 95% CI 0.70-1.05) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetics – While there is no well-established model of a genetic basis for cervical cancer, population studies have shown an increased incidence of cervical cancer within families. In the past, such familial clustering had been attributed to shared environmental exposures. However, subsequent data comparing full and half-siblings have demonstrated that heritable risk factors far outweigh the shared environmental components. As an example, a Swedish study of over 9000 siblings or half-siblings with cervical cancer or precancer attributed 64 percent of cases to genetics and only 36 percent to environmental exposures [<a href="#rid37">37</a>]. Investigations are ongoing to identify genetic alterations that may make patients less likely to clear persistent HPV infections and more susceptible to the development of cervical cancer. Findings to-date include an association of cervical cancer with a large variety of polymorphisms in a wide variety of genes, including germline variants [<a href="#rid38">38</a>], and those that regulate immunity and susceptibility [<a href="#rid39">39</a>], cytokine production [<a href="#rid40">40,41</a>], angiogenesis [<a href="#rid40">40</a>], tumor suppressor pathways [<a href="#rid42">42,43</a>], and signal transducers and activators of transcription pathways [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical cancer is <strong>less</strong> common in patients whose sexual partners are circumcised males [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/6716.html" rel="external">"Neonatal circumcision: Risks and benefits", section on 'Cervical cancer in partners'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Human papillomavirus (HPV) is central to the development of cervical neoplasia and can be detected in 99.7 percent of cervical cancers [<a href="#rid2">2</a>]. The virology and molecular pathogenesis of HPV-associated malignancies are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8031.html" rel="external">"Virology of human papillomavirus infections and the link to cancer"</a>.)</p><p>Among the more than 40 genital mucosal HPV types identified, approximately 15 are known to be oncogenic  (<a class="graphic graphic_table graphicRef76394" href="/d/graphic/76394.html" rel="external">table 1</a>). Subtypes HPV 16 and 18 are found in over 70 percent of all cervical cancers.</p><p>There are four major steps in cervical cancer development [<a href="#rid45">45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Oncogenic HPV infection of the metaplastic epithelium at the cervical transformation zone (the junction between the squamous epithelium of the ectocervix and the glandular epithelium of the endocervical canal).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistence of the HPV infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progression of a clone of epithelial cells from persistent viral infection to precancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development of carcinoma and invasion through the basement membrane.</p><p></p><p>While genital tract HPV infection is extremely common, cervical cancer results in only a small proportion of infected patients. It has been estimated that 75 to 80 percent of sexually active adults will acquire genital tract HPV before the age of 50 [<a href="#rid46">46,47</a>]. Most HPV infections are transient, and the virus alone is not sufficient to cause cervical neoplasia. When HPV infection persists, the time from initial infection to development of high-grade cervical intraepithelial neoplasia and, finally, invasive cancer takes an average of 15 years, although more rapid courses have been reported [<a href="#rid48">48</a>]. </p><p>Herpes simplex virus-2 infection as a cofactor in cervical cancer pathogenesis has been reported in some, but not all, studies [<a href="#rid49">49-52</a>]. Further investigation of this issue is needed.</p><p>The disease burden of genital HPV infection includes conditions other than cervical cancer, including anogenital warts, and cancer of the vulva, vagina, anus, and penis [<a href="#rid53">53,54</a>]. (See  <a class="medical medical_review" href="/d/html/8314.html" rel="external">"Human papillomavirus infections: Epidemiology and disease associations"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The most common histologic types of cervical cancer are squamous cell carcinoma and adenocarcinoma; such cancers can be HPV associated or HPV independent [<a href="#rid55">55</a>]. The histopathologic types of cervical cancer are listed in the table  (<a class="graphic graphic_table graphicRef141016" href="/d/graphic/141016.html" rel="external">table 2</a>). </p><p>The distribution of histologic types in the United States is [<a href="#rid56">56,57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Squamous cell carcinoma – 75 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adenocarcinoma (including adenosquamous) – 25 percent; the incidence of invasive cervical adenocarcinoma and its variants has increased dramatically over the past few decades, particularly in younger patients [<a href="#rid56">56,58,59</a>]. (See  <a class="medical medical_review" href="/d/html/13929.html" rel="external">"Invasive cervical adenocarcinoma", section on 'Epidemiology and risk factors'</a>.)</p><p></p><p class="bulletIndent1">Adenosquamous tumors exhibit both glandular and squamous differentiation. They may be associated with a poorer outcome than squamous cell cancers or adenocarcinomas [<a href="#rid60">60-62</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other histologies – Neuroendocrine or small cell carcinomas can originate in the cervix in patients but are infrequent [<a href="#rid63">63</a>]. Rhabdomyosarcoma of the cervix is rare and typically occurs in young patients [<a href="#rid64">64,65</a>]. Primary cervical lymphoma and cervical sarcoma are also rare [<a href="#rid66">66-68</a>]. (See  <a class="medical medical_review" href="/d/html/7728.html" rel="external">"Rhabdomyosarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging"</a> and  <a class="medical medical_review" href="/d/html/13930.html" rel="external">"Small cell neuroendocrine carcinoma of the cervix", section on 'Introduction'</a> and  <a class="medical medical_review" href="/d/html/13929.html" rel="external">"Invasive cervical adenocarcinoma"</a>.)</p><p></p><p>Human papillomavirus (HPV) subtypes associated with squamous cell carcinoma are different from those associated with adenocarcinoma. In an international study of over 30,000 cervical cancers, the distribution of HPV subtypes was [<a href="#rid69">69</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Squamous cell carcinoma – HPV 16 (59 percent of cases), 18 (13 percent), 58 (5 percent), 33 (5 percent), 45 (4 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adenocarcinoma – HPV 16 (36 percent), 18 (37 percent), 45 (5 percent), 31 (2 percent), 33 (2 percent).</p><p></p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Early cervical cancer is frequently asymptomatic, underscoring the importance of screening. In asymptomatic patients, cervical cancer may be discovered as a result of cervical cancer screening or incidentally if a visible lesion is discovered upon pelvic examination. (See  <a class="medical medical_review" href="/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a> and <a class="local">'Physical examination'</a> below.)</p><p>For those with symptoms, the most common ones at presentation are [<a href="#rid70">70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Irregular or heavy vaginal bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>Postcoital bleeding</p><p></p><p>Some patients present with a vaginal discharge that may be watery, mucoid, or purulent and malodorous. This is a nonspecific finding and may be mistaken for vaginitis or cervicitis. </p><p>Approximately 44 percent of patients have localized disease at diagnosis, 34 percent have regional disease, and 15 percent have distant metastases [<a href="#rid1">1</a>]. Advanced disease may present with pelvic or lower back pain, which may radiate along the posterior side of the lower extremities. Bowel or urinary symptoms, such as pressure-related complaints, hematuria, hematochezia, or vaginal passage of urine or stool, are uncommon and suggest advanced disease. A discussion regarding how cervical cancer spreads and its staging is found elsewhere. (See  <a class="medical medical_review" href="/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of cervical cancer is made based upon histologic evaluation of a cervical biopsy.</p><p class="headingAnchor" id="H1087482"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>A pelvic examination should be performed in any patient with symptoms suggestive of cervical cancer. Visualization of the cervix upon speculum examination may reveal a normal appearance or a visible cervical lesion; large tumors may appear to replace the cervix entirely. Any lesion that is visible should be biopsied regardless of previous benign cervical cytology results [<a href="#rid71">71</a>]. The only visible lesions that do not require biopsy are Nabothian cysts and only when this diagnosis is confirmed by an experienced examiner. (See  <a class="medical medical_review" href="/d/html/5428.html" rel="external">"Benign cervical lesions and congenital anomalies of the cervix", section on 'Nabothian cysts'</a>.)</p><p>Cervical cancer usually originates at the transformation zone (the junction between the squamous epithelium of the ectocervix and the glandular epithelium of the endocervical canal). The lesion may manifest as a superficial ulceration, exophytic tumor in the exocervix, or infiltration of the endocervix. Endophytic tumors can result in a cervix that appears enlarged, smooth, and indurated, often referred to as a "barrel shaped cervix." Among cervical adenocarcinomas, approximately one-half are exophytic, others diffusely enlarge or ulcerate the cervix, and approximately 15 percent have no visible lesion because the carcinoma is within the endocervical canal.</p><p>A thorough pelvic examination, including rectovaginal examination with assessment of tumor size and vaginal or parametrial involvement, is required for staging cervical cancer. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes", section on 'Staging procedure'</a>.)</p><p>Other suspicious physical examination findings are palpable groin or supraclavicular lymph nodes. </p><p class="headingAnchor" id="H1088023"><span class="h2">Cervical cytology</span><span class="headingEndMark"> — </span>Cervical cytology is the principal method for cervical cancer screening in the United States and is the method of choice when cervical cancer is suspected. In other countries, such as Australia, the United Kingdom, and Netherlands, human papillomavirus (HPV) testing is the principal method for cervical cancer screening, with cervical cytology being performed only if the HPV high-risk nucleic acid test is positive. </p><p>Cervical cancer screening, techniques for cervical cytology testing, the use of HPV testing, and interpretation of results are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a> and  <a class="medical medical_review" href="/d/html/3219.html" rel="external">"Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing"</a> and  <a class="medical medical_review" href="/d/html/3205.html" rel="external">"Cervical cancer screening: The cytology and human papillomavirus report"</a>.)</p><p class="headingAnchor" id="H1087497"><span class="h2">Cervical biopsy and colposcopy</span><span class="headingEndMark"> — </span>Cervical biopsy may be performed as part of an initial evaluation or along with a full staging procedure, depending on the level of suspicion of malignancy and the patient's access to health care. The approach to cervical biopsy differs depending upon the patient's presentation and findings on pelvic examination:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a grossly visible lesion, a suspected diagnosis of cancer must be confirmed by a biopsy of the lesion. We prefer to take the biopsy from the area of the lesion that looks most suspicious with care to avoid grossly necrotic areas, as these are often nondiagnostic. Any cervix that is unusually firm or expanded should be sampled by punch biopsy and endocervical curettage, even if the cervical cytology test does not show evidence of neoplasia. Biopsy in patients with gross lesions may result in significant bleeding and even hemorrhage, and practitioners should be adequately prepared with hemostatic agents such as Monsel solution and the ability to pack the vagina should bleeding be significant. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients without a visible lesion (eg, symptomatic, abnormal cervical cytology) should undergo colposcopy with directed biopsy. Patients in settings in which colposcopy is not available may undergo directed biopsy with the aid of visual inspection methods. (See  <a class="medical medical_review" href="/d/html/3260.html" rel="external">"Colposcopy"</a> and  <a class="medical medical_review" href="/d/html/3202.html" rel="external">"Screening for cervical cancer in resource-limited settings", section on 'Alternate: Visual inspection methods'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical conization or loop electrosurgical excision procedure is necessary if malignancy is suspected but is not found with directed cervical biopsies (eg, some patients with high-grade cervical intraepithelial neoplasia, inadequate colposcopy, and in patients with an endocervical curettage that is positive for moderate to severe dysplasia). Conization is also required in the setting of microinvasive cancer to determine whether conservative or radical surgery is required for treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Techniques for colposcopy and cervical biopsy are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3260.html" rel="external">"Colposcopy"</a>.)</p><p></p><p class="headingAnchor" id="H1088427"><span class="h2">Other diagnostic modalities</span><span class="headingEndMark"> — </span>Imaging studies are not typically part of cervical cancer diagnosis, although some are used for staging and evaluation of patients with known malignancy. (See  <a class="medical medical_review" href="/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes", section on 'Staging procedure'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of cervical cancer includes other conditions that result in irregular or heavy vaginal bleeding, vaginal discharge, or a visible cervical lesion. Postcoital bleeding, which is the most specific presentation of cervical cancer, may also result from cervicitis and other benign conditions. Evaluation of patients with these conditions is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5421.html" rel="external">"Approach to the patient with postmenopausal uterine bleeding"</a> and  <a class="medical medical_review" href="/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation"</a>.)</p><p>Benign tumor-like lesions that may mimic cervical cancer include Nabothian cysts, mesonephric cysts, cervical ectropion, ulcers associated with sexually transmitted infections, reactive glandular changes from inflammation, and endometriosis. (See  <a class="medical medical_review" href="/d/html/5428.html" rel="external">"Benign cervical lesions and congenital anomalies of the cervix"</a>.)</p><p class="headingAnchor" id="H3893440677"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117738.html" rel="external">"Society guideline links: Cervical cancer screening, prevention, and management"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113940.html" rel="external">"Society guideline links: Treatment of cervical cancer"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15414.html" rel="external">"Patient education: Cervical cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/859.html" rel="external">"Patient education: Cervical cancer treatment; early-stage cancer (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/868.html" rel="external">"Patient education: Fertility preservation in early-stage cervical cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cancer of the uterine cervix is the third most common cancer diagnosis and cause of death among gynecologic cancers in the United States. In countries that do not have access to cervical cancer screening and prevention programs, cervical cancer remains the second most common type of cancer and third most common cause of cancer deaths among all types of cancer in females. (See <a class="local">'Incidence and mortality'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The lifetime risk of developing cervical cancer for United States females is 0.7 percent. The median age at diagnosis of cervical cancer in the United States is 50 years old. (See <a class="local">'Age distribution'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Human papillomavirus (HPV) is central to the development of cervical neoplasia and can be detected in 99.7 percent of cervical cancers. Subtypes HPV 16 and 18 are found in over 70 percent of all cervical cancers  (<a class="graphic graphic_table graphicRef76394" href="/d/graphic/76394.html" rel="external">table 1</a>). (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for cervical cancer are mostly associated with an increased risk of acquiring or having a compromised immune response to HPV infection; these include early onset of sexual activity, multiple sexual partners, a high-risk sexual partner, history of sexually transmitted infections, history of vulvar or vaginal squamous intraepithelial neoplasia or cancer, and immunosuppression. Oral contraceptive use appears to be associated with an increased risk of cervical cancer. Cigarette smoking appears to be associated with an increased risk of squamous cell cancer but not adenocarcinoma. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – The most common histologic types of cervical cancer are squamous cell (75 percent of cervical cancers) and adenocarcinoma (25 percent). The histopathologic types of cervical cancer are listed in the table  (<a class="graphic graphic_table graphicRef141016" href="/d/graphic/141016.html" rel="external">table 2</a>). (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Early cervical cancer is frequently asymptomatic, emphasizing the importance of screening. The most common symptoms at presentation are abnormal vaginal bleeding (including postcoital bleeding) and vaginal discharge. A lesion may or may not be visible or palpable on physical examination. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Physical examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of cervical cancer is established by biopsy. Symptomatic patients without a visible lesion and those who have only abnormal cervical cytology should undergo colposcopy with directed biopsy and, if necessary, diagnostic conization. (See <a class="local">'Diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.</a></li><li><a class="nounderline abstract_t">Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12.</a></li><li class="breakAll">Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute; Bethesda, MD 2007.</li><li><a class="nounderline abstract_t">Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71:209.</a></li><li><a class="nounderline abstract_t">Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394.</a></li><li><a class="nounderline abstract_t">Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87.</a></li><li class="breakAll">WHO/ICO Information Center of HPV and Cervical Cancer (HPV Information Center). Human Papillomavirus and Related Cancers in the World. Summary Report 2010. http://www.who.int/hpvcentre/en/ (Accessed on September 19, 2011).</li><li><a class="nounderline abstract_t">Jedy-Agba E, Joko WY, Liu B, et al. Trends in cervical cancer incidence in sub-Saharan Africa. Br J Cancer 2020; 123:148.</a></li><li><a class="nounderline abstract_t">Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318:904.</a></li><li><a class="nounderline abstract_t">Willoughby BJ, Faulkner K, Stamp EC, Whitaker CJ. A descriptive study of the decline in cervical screening coverage rates in the North East and Yorkshire and the Humber regions of the UK from 1995 to 2005. J Public Health (Oxf) 2006; 28:355.</a></li><li><a class="nounderline abstract_t">Ortiz AP, Ortiz-Ortiz KJ, Colón-López V, et al. Incidence of Cervical Cancer in Puerto Rico, 2001-2017. JAMA Oncol 2021; 7:456.</a></li><li><a class="nounderline abstract_t">Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine 2014; 32:733.</a></li><li><a class="nounderline abstract_t">Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377:2085.</a></li><li><a class="nounderline abstract_t">Niccolai LM, Julian PJ, Meek JI, et al. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. Cancer Epidemiol Biomarkers Prev 2013; 22:1446.</a></li><li class="breakAll">SEER Cancer Stat Facts: Cervix Uteri Cancer. https://seer.cancer.gov/statfacts/html/cervix.html (Accessed on May 28, 2023).</li><li><a class="nounderline abstract_t">Beavis AL, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer 2017; 123:1044.</a></li><li><a class="nounderline abstract_t">Shahmoradi Z, Damgacioglu H, Clarke MA, et al. Cervical Cancer Incidence Among US Women, 2001-2019. JAMA 2022; 328:2267.</a></li><li><a class="nounderline abstract_t">Stang A, Hawk H, Knowlton R, et al. Hysterectomy-corrected incidence rates of cervical and uterine cancers in Massachusetts, 1995 to 2010. Ann Epidemiol 2014; 24:849.</a></li><li><a class="nounderline abstract_t">International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007; 120:885.</a></li><li><a class="nounderline abstract_t">Castellsagué X, Bosch FX, Muñoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346:1105.</a></li><li><a class="nounderline abstract_t">Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285:47.</a></li><li><a class="nounderline abstract_t">Wallin KL, Wiklund F, Luostarinen T, et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer 2002; 101:371.</a></li><li><a class="nounderline abstract_t">Hawes SE, Kiviat NB. Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer? J Natl Cancer Inst 2002; 94:1592.</a></li><li><a class="nounderline abstract_t">Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002; 94:1406.</a></li><li><a class="nounderline abstract_t">International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118:1481.</a></li><li><a class="nounderline abstract_t">Muñoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359:1093.</a></li><li><a class="nounderline abstract_t">International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006; 119:1108.</a></li><li><a class="nounderline abstract_t">International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370:1609.</a></li><li><a class="nounderline abstract_t">Waggoner SE, Darcy KM, Tian C, Lanciano R. Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Am J Obstet Gynecol 2010; 202:283.e1.</a></li><li class="breakAll">Singh GK, Miller BA, Hankey BF, Edwards BK. Area Socioeconomic Variations in U.S. Cancer Incidence, 1975-1999. National Cancer Institute; Bethesda, MD 2003.</li><li><a class="nounderline abstract_t">Yoo W, Kim S, Huh WK, et al. Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One 2017; 12:e0172548.</a></li><li><a class="nounderline abstract_t">Yu L, Sabatino SA, White MC. Rural-Urban and Racial/Ethnic Disparities in Invasive Cervical Cancer Incidence in the United States, 2010-2014. Prev Chronic Dis 2019; 16:E70.</a></li><li><a class="nounderline abstract_t">Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013; 22:1931.</a></li><li><a class="nounderline abstract_t">Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J 2003; 9:348.</a></li><li><a class="nounderline abstract_t">Green J, Berrington de Gonzalez A, Sweetland S, et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer. Br J Cancer 2003; 89:2078.</a></li><li><a class="nounderline abstract_t">Minalt N, Caldwell A, Yedlicka GM, et al. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. Am J Obstet Gynecol 2023; 229:93.</a></li><li><a class="nounderline abstract_t">Hemminki K, Chen B. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev 2006; 15:1413.</a></li><li><a class="nounderline abstract_t">Wen H, Xu Q, Sheng X, et al. Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers. JAMA Netw Open 2023; 6:e2326437.</a></li><li><a class="nounderline abstract_t">Liu L, Yang X, Chen X, et al. Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep 2012; 39:2683.</a></li><li><a class="nounderline abstract_t">Grimm C, Watrowski R, Baumühlner K, et al. Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol 2011; 121:537.</a></li><li><a class="nounderline abstract_t">Wang Q, Zhang C, Walayat S, et al. Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol 2011; 158:330.</a></li><li><a class="nounderline abstract_t">Craveiro R, Bravo I, Catarino R, et al. The role of p73 G4C14-to-A4T14 polymorphism in the susceptibility to cervical cancer. DNA Cell Biol 2012; 31:224.</a></li><li><a class="nounderline abstract_t">Wang L, Gao R, Yu L. Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk. Mol Biol Rep 2012; 39:1731.</a></li><li><a class="nounderline abstract_t">Wang K, Zhou B, Zhang J, et al. Association of signal transducer and activator of transcription 3 gene polymorphisms with cervical cancer in Chinese women. DNA Cell Biol 2011; 30:931.</a></li><li><a class="nounderline abstract_t">Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890.</a></li><li><a class="nounderline abstract_t">Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis 2006; 33:502.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Society of Gynecologic Oncologists Education Resource Panel Writing group, Collins Y, Einstein MH, et al. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol 2006; 102:552.</a></li><li><a class="nounderline abstract_t">Jones C. Cervical cancer: is herpes simplex virus type II a cofactor? Clin Microbiol Rev 1995; 8:549.</a></li><li><a class="nounderline abstract_t">Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94:1604.</a></li><li><a class="nounderline abstract_t">Lehtinen M, Koskela P, Jellum E, et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. Am J Epidemiol 2002; 156:687.</a></li><li><a class="nounderline abstract_t">Kjaer SK, de Villiers EM, Cağlayan H, et al. Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark)--a second look. Br J Cancer 1993; 67:830.</a></li><li><a class="nounderline abstract_t">Kayes O, Ahmed HU, Arya M, Minhas S. Molecular and genetic pathways in penile cancer. Lancet Oncol 2007; 8:420.</a></li><li><a class="nounderline abstract_t">Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24 Suppl 3:S3/11.</a></li><li class="breakAll">WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon (France): International Agency for Research on Cancer; 2020. (WHO classification of tumours series, 5th ed.; vol. 4). https://publications.iarc.fr/592. (Accessed on February 23, 2023).</li><li><a class="nounderline abstract_t">Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) 2012; 21:1031.</a></li><li><a class="nounderline abstract_t">Stolnicu S, Soslow RA. Squamous and Glandular Epithelial Tumors of the Cervix: A Pragmatical Review Emphasizing Emerging Issues in Classification, Diagnosis, and Staging. Surg Pathol Clin 2022; 15:369.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995; 59:38.</a></li><li><a class="nounderline abstract_t">Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol 2000; 78:97.</a></li><li><a class="nounderline abstract_t">Look KY, Brunetto VL, Clarke-Pearson DL, et al. An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 63:304.</a></li><li><a class="nounderline abstract_t">Grisaru D, Covens A, Chapman B, et al. Does histology influence prognosis in patients with early-stage cervical carcinoma? Cancer 2001; 92:2999.</a></li><li><a class="nounderline abstract_t">Lea JS, Coleman RL, Garner EO, et al. Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol 2003; 91:558.</a></li><li><a class="nounderline abstract_t">Albores-Saavedra J, Gersell D, Gilks CB, et al. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 1997; 121:34.</a></li><li><a class="nounderline abstract_t">Behtash N, Mousavi A, Tehranian A, et al. Embryonal rhabdomyosarcoma of the uterine cervix: case report and review of the literature. Gynecol Oncol 2003; 91:452.</a></li><li><a class="nounderline abstract_t">Villella JA, Bogner PN, Jani-Sait SN, et al. Rhabdomyosarcoma of the cervix in sisters with review of the literature. Gynecol Oncol 2005; 99:742.</a></li><li><a class="nounderline abstract_t">Dursun P, Gultekin M, Bozdag G, et al. Primary cervical lymphoma: report of two cases and review of the literature. Gynecol Oncol 2005; 98:484.</a></li><li><a class="nounderline abstract_t">Kendrick JE 4th, Straughn JM Jr. Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies. Gynecol Oncol 2005; 98:490.</a></li><li><a class="nounderline abstract_t">Wright JD, Rosenblum K, Huettner PC, et al. Cervical sarcomas: an analysis of incidence and outcome. Gynecol Oncol 2005; 99:348.</a></li><li><a class="nounderline abstract_t">Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128:927.</a></li><li class="breakAll">DiSaia PJ, Creasman WT. Invasive cervical cancer. In: Clinical Gynecologic Oncology, 7th ed., Mosby Elsevier, Philadelphia 2007. p.55.</li><li><a class="nounderline abstract_t">Partridge EE, Abu-Rustum NR, Campos SM, et al. Cervical cancer screening. J Natl Compr Canc Netw 2010; 8:1358.</a></li></ol></div><div id="topicVersionRevision">Topic 3179 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451482" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451482" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30207593" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651787" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Global cancer statistics, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651787" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Global cancer statistics, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32336751" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trends in cervical cancer incidence in sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10102852" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062818" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A descriptive study of the decline in cervical screening coverage rates in the North East and Yorkshire and the Humber regions of the UK from 1995 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33443548" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Incidence of Cervical Cancer in Puerto Rico, 2001-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24291200" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21684381" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23704476" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23704476" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28112816" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409512" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cervical Cancer Incidence Among US Women, 2001-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25241148" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hysterectomy-corrected incidence rates of cervical and uterine cancers in Massachusetts, 1995 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17131323" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11948269" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11150108" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209962" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12419778" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12237286" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16206285" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11943256" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16570271" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17993361" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20044066" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20044066" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28234949" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31172917" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rural-Urban and Racial/Ethnic Disparities in Invasive Cervical Cancer Incidence in the United States, 2010-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24014598" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14690309" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The epidemiology of cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14647141" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: the UK National Case-Control Study of Cervical Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37001577" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16835346" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Familial risks for cervical tumors in full and half siblings: etiologic apportioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37523182" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670964" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Association between TNF-αpolymorphisms and cervical cancer risk: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376376" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719187" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association between cytokine gene polymorphisms and cervical cancer in a Chinese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21711160" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The role of p73 G4C14-to-A4T14 polymorphism in the susceptibility to cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21617940" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668356" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Association of signal transducer and activator of transcription 3 gene polymorphisms with cervical cancer in Chinese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17826171" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Human papillomavirus and cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16572039" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16979432" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8665469" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cervical cancer: is herpes simplex virus type II a cofactor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12419786" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370156" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8385982" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark)--a second look.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17466899" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Molecular and genetic pathways in penile cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16949997" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Chapter 2: The burden of HPV-related cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16949997" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Chapter 2: The burden of HPV-related cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22816437" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cervical cancer trends in the United States: a 35-year population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35715166" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Squamous and Glandular Epithelial Tumors of the Cervix: A Pragmatical Review Emphasizing Emerging Issues in Classification, Diagnosis, and Staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7557613" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926787" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8946863" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11753977" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Does histology influence prognosis in patients with early-stage cervical carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675676" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9111090" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14599884" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Embryonal rhabdomyosarcoma of the uterine cervix: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214206" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Rhabdomyosarcoma of the cervix in sisters with review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15992915" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Primary cervical lymphoma: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15993934" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051326" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cervical sarcomas: an analysis of incidence and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20473886" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20473886" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21147902" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cervical cancer screening.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
